Inhibikase Therapeutics, Inc. (IKT)
$1.97+3.14%Close
SELLCRISIS · day 13
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $260M
- Beta
- 0.90
- P/E (TTM)
- -4.17
- Short % float
- 12.03%
- Days to cover
- 27.0
- SI change
- +4.9%
- 1W
- -1.50%
- 1M
- -15.45%
- vs SPY 1W
- -2.66%
- vs SPY 1M
- -18.44%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on IKT?
- LOPJLB’s latest quantitative signal on Inhibikase Therapeutics, Inc. (IKT) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is IKT in?
- Inhibikase Therapeutics, Inc. (IKT) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Inhibikase Therapeutics, Inc. (IKT) do?
- Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of i…